ASC Therapeutics

ASC Therapeutics develops biopharmaceuticals based on proprietary gene, CRISPR and allogeneic cell therapies

[ASC Therapeutics @asctherapeutics]

Dosing the first patient of our phase I/IIa clinical trial for ASC618, is very meaningful for patients with hemophilia A hoping to access a more durable and affordable second-generation gene therapy. Learn more in our press release https://t.co/U6r6RFydZg

[Oscar Segurado, MD PhD @Oscarsegurado]

Join me at the Chief Medical Officer Summit 360˚ in Boston on April 17-18! As a CMO, I am excited to discuss managing and motivating biotech teams while networking with like-minded professionals. Looking forward to gaining fresh insights and meeting fellow CMOs at #CMO360

[Oscar Segurado, MD PhD @Oscarsegurado]

… the lifetime cost for patients with severe Hemophilia A is over $21 million…
https://t.co/8LGUu2a3aT

[Oscar Segurado, MD PhD @Oscarsegurado]

Congratulations to the editors and fellow authors for the culmination of this extraordinary effort to coalesce industry perspectives on the development of gene therapies!

[Oscar Segurado, MD PhD @Oscarsegurado]

Many patients with metastatic cancer have died, are dying and will die if we don’t replace the conventional way of classifying metastatic cancers according to their organ of origin and embrace AI-driven molecular, cellular and protein fingerprinting
https://t.co/n0KYlSfRgP

[Medical Affairs @medicaffairs]

The immunological revolution of cell-based therapies for autoimmune disorders has just started
https://t.co/eangglZDRI

[Medical Affairs @medicaffairs]

https://t.co/UPmUQnGyNt

[Oscar Segurado, MD PhD @Oscarsegurado]

Thanks, Charles Cormier, for this fun and inspiring interview. Always glad to talk about synthetic medicine and the mind-antibody connection
https://t.co/TxW6H6KhDZ

[Oscar Segurado, MD PhD @Oscarsegurado]

Ever wondered how far we’ve truly come in the realm of gene and cell therapies, and where we’re headed next? This captivating conversation with Oscar Segurado, the CMO of ASC Therapeutics, will satisfy your curiosity https://t.co/dUU709IAI0

[ASC Therapeutics @asctherapeutics]

Hemophilia News Today highlights our potentially more durable and affordable second-generation gene therapy ASC618 in people with hemophilia A. https://t.co/RpvGKBla5G

[ASC Therapeutics @asctherapeutics]

Our board member professor Behnam Sadeghi, Karolinska University Sweden, and our CEO Ruhong Jiang were keynote speaker and panelist at the 5th World Science and Technology Forum in Shenzen, China. Discussed our IND-cleared allogeneic cell therapy for GVHD

[Medical Affairs @medicaffairs]

A personalized medicine approach through the combination of single biomarkers to develop signatures with AI, proven safe and effective in multiple oncology studies, still requires a significant effort to accelerate its adoption as standard of care https://t.co/flCIhL5yuC

[Medical Affairs @medicaffairs]

Learn about Decentralized Clinical Trials in this Clinical Leader Webinar
https://t.co/XJk2FJiOrX

[Oscar Segurado, MD PhD @Oscarsegurado]

Our publication is now available OPEN ACCESS:
Novel therapies for graft versus host disease with a focus on cell therapies https://t.co/5WSeGvkJv1

[ASC Therapeutics @asctherapeutics]

Elated to have our paper on Cell Therapies for GVHD published in Frontiers in Immunology!

https://t.co/LbtR43xR3I

[Oscar Segurado, MD PhD @Oscarsegurado]

Clinical Leader Live’s interactive webinar on how ASC Therapeutics and other sponsors are adapting to DCTs … hybrid, virtual, remote, home-based,… Register for free here:
https://t.co/5WLVCncBgy

[Oscar Segurado, MD PhD @Oscarsegurado]

Establish robust internal communication channels to ensure everyone can express opinions, ask questions and feel trusted and valued
https://t.co/RjSs2jJKkl

[ASC Therapeutics @asctherapeutics]

Key drivers of our successful clinical programs https://t.co/s0hEZCSXnu

[Oscar Segurado, MD PhD @Oscarsegurado]

Looking forward to our Workshop on May 22
https://t.co/DGGXhSnf3I

[Medhealth Outlook @Mdhealthoutlook]

Biotechnological Requirements for Patient Monitoring in Gene Therapies https://t.co/ceugvRMWi9 Oscar Segurado @Oscarsegurado @asctherapeutics ASC Therapeutics #tech #technology #CRO #clinicalresearch #Biotechnological #bio